Understand the source comparison
Dihexa Compare to Other Research Peptides: Full Comparison
Before selecting a cognitive peptide for any research protocol, the mechanism, administration route, half-life, and primary endpoints must align with the study's objectives. The table below compares dihexa to the most commonly used cognitive and neurotrophic p
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a cognitive peptide for any research protocol, the mechanism, administration route, half-life, and primary endpoints must align with the study's objectives. The table below compares dihexa to the most commonly used cognitive and neurotrophic peptides across key parameters.
- Dihexa
- c-Met receptor agonism → synaptogenesis via HGF pathway
- Yes (oral bioavailable)
- Oral, subcutaneous
- Once daily
- Neurodegeneration models, synaptic density studies, hippocampal plasticity
- Only orally bioavailable neurotrophic peptide with direct synaptogenic action. Best for chronic structural endpoints
- Semax
- Acetylcholine modulation, BDNF upregulation
- Limited (intranasal required)
- Intranasal spray
- Twice daily
- Acute cognitive enhancement, attention, working memory
- Excellent for short-term cognitive boost models but lacks structural neurotrophic effects
- Cerebrolysin
- BDNF/GDNF/NGF fragment delivery
- No (IV required)
- Intravenous infusion
- Daily (clinical protocols)
- Stroke recovery, TBI models, dementia research
- Proven neurotrophic effects but batch variability and IV-only route limit experimental flexibility
- Selank
- Anxiolytic via GABA modulation, immune regulation
- Once or twice daily
- Anxiety models, stress response, immune function
- Strong anxiolytic profile but minimal direct cognitive or synaptic effects
- Noopept
- AMPA receptor modulation, mild BDNF increase
- Partial (oral possible but low)
- Oral, sublingual
- Memory consolidation, neuroprotection studies
- Reliable but incremental. Doesn't produce structural plasticity at research doses
- P21 (CNTF derivative)
- CNTF receptor activation → neurogenesis
- Yes (subcutaneous)
- Subcutaneous injection
- Daily or every 48h
- Neurogenesis models, hippocampal cell proliferation
- Potent neurogenic effects but short half-life and injection requirement complicate protocols